![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Madrid, Spain:
The polypill developed by the CNIC and Ferrer, which incorporates three medicine (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is efficient at stopping secondary antagonistic cardiovascular occasions in individuals who have beforehand had a coronary heart assault. The polypill reduces mortality from cardiovascular causes in this inhabitants by 33%.
This press launch options multimedia. View the complete launch right here: https://www.businesswire.com/news/home/20220826005012/en/
Dr. Valentín Fuster, principal investigator of the SECURE examine, CNIC General Director, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital Credit: Jordi Bardajil
This is the discovering of the SECURE examine, coordinated by the Spanish National Center for Cardiovascular Research (CNIC). The examine outcomes had been offered at present in a Hot Line session on the European Society of Cardiology assembly (ESC 2022) in Barcelona and are printed in The New England Journal of Medicine (NEJM)1.
Dr. Valentín Fuster, principal investigator of the SECURE examine, CNIC General Director, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, mentioned “the results of the SECURE study show for the first time that the polypill achieves clinically relevant reductions in the recurrent cardiovascular events among people who have recovered from a previous heart attack”.
SECURE included 2499 sufferers from 7 European nations (Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary) recovering after a myocardial infarction. The examine members had been randomly assigned to obtain customary remedy or the CNIC polypill*. The common age of the members was 76 years, and 31% had been ladies. The examine inhabitants included 77.9% with hypertension, 57.4% with diabetes, and 51.3% with a historical past of tobacco smoking.
The SECURE trial analyzed the incidence of 4 main cardiovascular occasions: dying from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and emergency coronary revascularization (the restoration of blood move by way of a blocked coronary artery). The examine adopted sufferers for a median of three years and produced conclusive outcomes: sufferers taking the polypill had a 24% decrease threat of those 4 occasions than sufferers taking the three medicine individually.
The standout discovering of the examine is the impact of the polypill on the important thing consequence of cardiovascular associated dying, which confirmed a relative discount of 33%, from 71 sufferers in the group receiving customary remedy to only 48 in the polypill group.
The examine additionally discovered that sufferers in the polypill group had the next stage of remedy adherence than these in the management group, thus confirming the findings of the sooner FOCUS2 examine, additionally funded by the European Union.
According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “the 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia compared to standard treatment and it represents an important step in our mission to provide significant and differential value to people who suffer from serious health conditions”.
The SECURE trial was funded by the European Union Horizon 2020 analysis and innovation program (trial identifier NCT02596126).
- Polypill Strategy in Secondary Cardiovascular Prevention Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). 2022 Aug.
- Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L et al. A polypill technique to enhance adherence: outcomes from the FOCUS mission. J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82
* Trinomia®, Sincronium®, Iltria® comprises aspirin (100 mg), the ACE inhibitor ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg).
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220826005012/en/
